STOCK TITAN

Tiziana Life Sciences Ltd (TLSA) director adds 15,000 shares in open-market buy

(Neutral)
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Tiziana Life Sciences Ltd director and ten percent owner Gabriele M. Cerrone, through Panetta Partners Limited, purchased 15,000 shares of common stock in an open-market transaction at $1.11 per share on June 12, 2026, bringing indirect holdings to 44,772,230 shares. This amended report updates only the transaction code associated with that purchase.

Positive

  • None.

Negative

  • None.
Insider CERRONE GABRIELE M
Role Director, 10% Owner
Bought 15,000 shs ($17K)
Type Security Shares Price Value
Purchase COMMON STOCK 15,000 $1.11 $17K
Holdings After Transaction: COMMON STOCK — 44,772,230 shares (Indirect, Via Panetta Partners Limited)
Shares purchased 15,000 shares Open-market purchase of common stock on June 12, 2026
Purchase price $1.1100 per share Price for the 15,000-share common stock purchase
Indirect holdings after trade 44,772,230 shares Total TLSA common shares held indirectly via Panetta Partners Limited after the transaction
Net buy shares 15,000 shares Net share change across all reported non-derivative transactions in this filing
open market purchase financial
"transaction_code_description: "Purchase in open market or private transaction""
An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.
indirect ownership financial
"ownership_type: "indirect" with nature_of_ownership "Via Panetta Partners Limited""
ten percent owner financial
""is_ten_percent_owner": 1 for reporting person Gabriele M. Cerrone"
non-derivative financial
"transaction_type set to "non-derivative" for the common stock purchase"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did TLSA report in this Form 4/A amendment?

Tiziana Life Sciences Ltd reported that 15,000 common shares were purchased in an open-market transaction at $1.11 per share. The trade was made indirectly through Panetta Partners Limited.

When did the TLSA insider buy the 15,000 shares and at what price?

The TLSA insider purchase occurred on June 12, 2026 at a price of $1.11 per share. It was reported as a non-derivative, open-market transaction in common stock.

How many TLSA shares does the reporting person hold after this transaction?

Following the reported trade, the insider’s indirect holdings total 44,772,230 TLSA common shares. These shares are held via Panetta Partners Limited, as disclosed in the ownership information.

Who is the TLSA insider in this Form 4/A and what is their role?

The reporting person is Gabriele M. Cerrone, a director and ten percent owner of Tiziana Life Sciences Ltd. The purchase was made indirectly through Panetta Partners Limited on his behalf.

What change does this Form 4/A make to the earlier TLSA filing?

The amendment states it only corrects the transaction code linked to this open-market purchase. It confirms that no other reported transactions or economic details are affected by the correction.

Was the TLSA insider trade reported as part of a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked, so it does not state that the trade was made under a pre-arranged trading plan. No separate footnote describes it as a 10b5-1 transaction.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CERRONE GABRIELE M

(Last)(First)(Middle)
14-15 CONDUIT ST

(Street)
LONDONW1S2XJ

(City)(State)(Zip)

UNITED KINGDOM

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tiziana Life Sciences Ltd [ TLSA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
06/17/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
COMMON STOCK06/12/2026P15,000A$1.1144,772,230IVia Panetta Partners Limited
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
Remarks:
This Form 4/A amends the Form 4 filed on June 17, 2026 solely to correct the transaction code associated with this open market purchase. No other reported transactions are affected by this amendment.
/s/ Gabriele M. Cerrone08/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)